

# Steven Coutre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1638883/publications.pdf>

Version: 2024-02-01

100  
papers

11,849  
citations

101496

36  
h-index

40954

93  
g-index

100  
all docs

100  
docs citations

100  
times ranked

8457  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia. <i>Clinical Infectious Diseases</i> , 2022, 74, 1659-1668.	2.9	56
2	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	3.3	72
3	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1580-1588.	0.6	0
4	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.	3.3	12
5	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639.	0.6	27
6	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG) Tj ETQq0 006rgBT /Overlock 10	0.6	0
7	Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma. <i>JAAD Case Reports</i> , 2020, 6, 819-821.	0.4	2
8	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1278-1291.	6.3	393
9	Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML. <i>Blood</i> , 2020, 136, 36-37.	0.6	1
10	A one-two punch with VO KOs CLL. <i>Blood</i> , 2019, 133, 2737-2738.	0.6	0
11	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	2.0	305
12	Pooled Safety Summary for Patients Treated with the CD22-Directed Cytotoxin Moxetumomab Pasudotox-tdfk. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S275.	0.2	0
13	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019, 133, 2031-2042.	0.6	178
14	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 184-188.	1.2	10
15	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	2.0	27
16	Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. <i>Blood</i> , 2019, 134, 33-33.	0.6	29
17	ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 31-31.	0.6	47
18	Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib. <i>Journal of Clinical Oncology</i> , 2019, 37, 7510-7510.	0.8	1

#	ARTICLE	IF	CITATIONS
19	ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2019, 37, TPS7566-TPS7566.	0.8	5
20	Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.. Journal of Clinical Oncology, 2019, 37, 7014-7014.	0.8	0
21	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood, 2018, 131, 2331-2334.	0.6	64
22	Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood, 2018, 131, 2782-2788.	0.6	18
23	Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood, 2018, 131, 1910-1919.	0.6	339
24	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood, 2018, 131, 1415-1424.	0.6	160
25	Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood, 2018, 131, 1704-1711.	0.6	122
26	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2018, 19, 65-75.	5.1	314
27	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England Journal of Medicine, 2018, 379, 2517-2528.	13.9	706
28	Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Advances, 2018, 2, 1946-1956.	2.5	40
29	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 648-657.e15.	0.2	62
30	Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica, 2018, 103, e249-e251.	1.7	5
31	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 803-813.e7.	0.2	32
32	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology, 2018, 182, 504-512.	1.2	37
33	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica, 2018, 103, 1502-1510.	1.7	111
34	Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2018, 132, 3133-3133.	0.6	11
35	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Blood, 2018, 132, 6-6.	0.6	18
36	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematology,the, 2017, 4, e114-e126.	2.2	181

#	ARTICLE	IF	CITATIONS
37	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. <i>Blood</i> , 2017, 129, 1763-1767.	0.6	78
38	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. <i>British Journal of Haematology</i> , 2017, 178, 286-291.	1.2	55
39	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i> , 2017, 129, 2612-2615.	0.6	111
40	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , 2017, 102, 1796-1805.	1.7	200
41	Performance of the Karius Plasma Next Generation Sequencing Test in Determining the Etiologic Diagnosis of Febrile Neutropenia: Results from a Pilot Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, S613-S614.	0.4	3
42	Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy. <i>Blood</i> , 2017, 130, 834-834.	0.6	11
43	Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. <i>Journal of Clinical Oncology</i> , 2017, 35, 7510-7510.	0.8	11
44	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 768-778.	5.1	676
45	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 234-234.	0.6	36
46	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 4383-4383.	0.6	7
47	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. <i>British Journal of Haematology</i> , 2015, 171, 471-477.	1.2	36
48	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	13.9	1,261
49	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). <i>Blood</i> , 2015, 126, 495-495.	0.6	2
50	Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy. <i>Blood</i> , 2015, 126, 715-715.	0.6	26
51	Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. <i>Blood</i> , 2015, 126, LBA-6-LBA-6.	0.6	13
52	Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation. <i>Journal of Clinical Oncology</i> , 2015, 33, 7011-7011.	0.8	7
53	Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL). <i>Journal of Clinical Oncology</i> , 2015, 33, 7012-7012.	0.8	3
54	Safety and tolerability of the combination of ATRA + arsenic trioxide (ATO) + gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 7016-7016.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2015, 33, 7023-7023.	0.8	12
56	Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM).. Journal of Clinical Oncology, 2015, 33, 8532-8532.	0.8	3
57	Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.. Journal of Clinical Oncology, 2015, 33, e18030-e18030.	0.8	9
58	Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL. Blood, 2015, 126, 4153-4153.	0.6	1
59	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. New England Journal of Medicine, 2014, 371, 213-223.	13.9	1,427
60	SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. British Journal of Haematology, 2014, 165, 504-509.	1.2	73
61	Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation. Blood, 2014, 124, 1186-1186.	0.6	6
62	A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2014, 124, 1987-1987.	0.6	22
63	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. Blood, 2014, 124, 1990-1990.	0.6	10
64	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATEá,,ç-17 Trial. Blood, 2014, 124, 327-327.	0.6	33
65	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE™ Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2014, 124, 3331-3331.	0.6	24
66	Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses. Blood, 2014, 124, 3751-3751.	0.6	1
67	Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE™ Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2014, 124, 4696-4696.	0.6	12
68	Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant. Blood, 2014, 124, 4697-4697.	0.6	11
69	High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2013, 31, 676-683.	0.8	171
70	Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?. Cancer, 2013, 119, 1186-1194.	2.0	16
71	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 417-423.	0.6	56
72	Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 2012, 30, 1822-1828.	0.8	287

#	ARTICLE	IF	CITATIONS
73	Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 1096-1104.	5.1	58
74	Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 957-960.	2.0	22
75	CNS Relapse in Acute Promyelocytic Leukemia: Incidence, Management and Outcome. <i>Blood</i> , 2012, 120, 1489-1489.	0.6	12
76	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. <i>Blood</i> , 2011, 117, 3294-3301.	0.6	353
77	Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i> , 2010, 116, 3751-3757.	0.6	348
78	Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3015-3022.	0.8	181
79	Classification and Risk Stratification for Acute Promyelocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, S127-S129.	0.2	1
80	Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). <i>Blood</i> , 2010, 116, 1376-1376.	0.6	1
81	Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 $\beta$ , In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 1777-1777.	0.6	54
82	A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results. <i>Blood</i> , 2010, 116, 2516-2516.	0.6	6
83	Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies. <i>Blood</i> , 2010, 116, 3286-3286.	0.6	5
84	The Impact of Distance to Treatment Center on the Outcome of AML. <i>Blood</i> , 2010, 116, 4742-4742.	0.6	3
85	A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010, 116, 3288-3288.	0.6	0
86	Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. <i>Blood</i> , 2010, 116, 3313-3313.	0.6	0
87	Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.. <i>Blood</i> , 2009, 114, 1015-1015.	0.6	6
88	Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo $\text{\textcircled{R}}$ ) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.. <i>Blood</i> , 2009, 114, 3088-3088.	0.6	1
89	Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.. <i>Blood</i> , 2009, 114, 788-788.	0.6	17
90	Myelodysplastic syndromes: disease overview and therapy options. <i>Managed Care</i> , 2008, 17, 3-8.	0.3	3

#	ARTICLE	IF	CITATIONS
91	Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. <i>Blood</i> , 2007, 110, 2309-2315.	0.6	349
92	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , 2007, 109, 3207-3213.	0.6	400
93	Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?. <i>British Journal of Haematology</i> , 2007, 136, 379-392.	1.2	25
94	A Phase I Study of a Novel Human Monoclonal Antibody (mAb216) with Chemotherapy for the Treatment of Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007, 110, 2831-2831.	0.6	0
95	Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results.. <i>Blood</i> , 2006, 108, 3770-3770.	0.6	4
96	Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710.. <i>Blood</i> , 2006, 108, 566-566.	0.6	7
97	Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. <i>Seminars in Cancer Biology</i> , 2004, 14, 23-31.	4.3	9
98	Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. <i>Seminars in Cancer Biology</i> , 2004, 14, 307-315.	4.3	17
99	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. <i>Blood</i> , 2002, 99, 3530-3539.	0.6	1,096
100	United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 3852-3860.	0.8	773